New drug combo aims to flush out hidden HIV reservoirs

NCT ID NCT07053384

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This early-stage study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the amount of hidden HIV in the body. The study involves 107 adults with HIV, including those new to treatment and those already on standard therapy. The goal is to see if these combinations can shrink the viral reservoir, which is the main barrier to curing HIV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

San Diego, California, 92103, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Orlando, Florida, 32803, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

New York, New York, 10032, United States
GSK Investigational Site

Cincinnati, Ohio, 45267, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15213, United States
GSK Investigational Site

Dallas, Texas, 75208, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Brussels, 1000, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Aarhus, 8200, Denmark
GSK Investigational Site

Hvidovre, 2650, Denmark
GSK Investigational Site

Rotterdam, 3015 GD, Netherlands
GSK Investigational Site

Barcelona, 08003, Spain
GSK Investigational Site

Barcelona, 08026, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08916, Spain
GSK Investigational Site

Barcelona, 8907, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

La Laguna Santa Cruz, 38320, Spain
GSK Investigational Site

Madrid, 28020, Spain
GSK Investigational Site

Madrid, 28031, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28224, Spain
GSK Investigational Site

Palma de Mallorca, 07120, Spain
GSK Investigational Site

Palma de Mallorca, 7198, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Valencia, 46014, Spain
GSK Investigational Site

Valencia, 46026, Spain
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

London, SE1 7EH, United Kingdom
GSK Investigational Site

London, W2 1NY, United Kingdom

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS